P
Peter Atadja
Researcher at Novartis
Publications - 194
Citations - 16102
Peter Atadja is an academic researcher from Novartis. The author has contributed to research in topics: Histone deacetylase inhibitor & Panobinostat. The author has an hindex of 65, co-authored 191 publications receiving 14839 citations. Previous affiliations of Peter Atadja include University of Texas MD Anderson Cancer Center & Harvard University.
Papers
More filters
Journal ArticleDOI
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao,Joshua M. Korn,Stephane Ferretti,John Monahan,Youzhen Wang,Mallika Singh,Mallika Singh,Chao Zhang,Chao Zhang,Christian Schnell,Guizhi Yang,Yun Zhang,O. Alejandro Balbin,Stephanie Barbe,Hongbo Cai,Fergal Casey,Susmita Chatterjee,Derek Y. Chiang,Shannon Chuai,Shawn Cogan,Scott D. Collins,Ernesta Dammassa,Nicolas Ebel,Millicent Embry,John Green,Audrey Kauffmann,Colleen Kowal,Rebecca Leary,Joseph Lehar,Ying Liang,Alice Loo,Edward Lorenzana,E. Robert McDonald,Margaret E. McLaughlin,Jason Merkin,Ronald Meyer,Tara L. Naylor,Montesa Patawaran,Anupama Reddy,Anupama Reddy,Claudia Roelli,David A. Ruddy,Fernando Salangsang,Francesca Santacroce,Angad P Singh,Yan Tang,Walter Tinetto,Sonja Tobler,Roberto Velazquez,Kavitha Venkatesan,Fabian Von Arx,Hui Qin Wang,Zongyao Wang,Marion Wiesmann,Daniel Wyss,Fiona Xu,Hans Bitter,Peter Atadja,Emma Lees,Francesco Hofmann,En Li,Nicholas Keen,Robert Cozens,Michael Rugaard Jensen,Nancy Pryer,Nancy Pryer,Juliet Williams,William R. Sellers +67 more
TL;DR: The results suggest that PCTs may represent a more accurate approach than cell line models for assessing the clinical potential of some therapeutic modalities and could potentially improve preclinical evaluation of treatmentmodalities and enhance the ability to predict clinical trial responses.
Journal ArticleDOI
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS
Purva Bali,Michael Pranpat,James E. Bradner,Maria E. Balasis,Warren Fiskus,Fei Guo,Kathy Rocha,Sandhya Kumaraswamy,Sandhya Boyapalle,Peter Atadja,Edward Seto,Kapil N. Bhalla +11 more
TL;DR: It is demonstrated that in the Bcr-abl oncogene expressing human leukemia K562 cells,HDAC6 can be co-immunoprecipitated with HSP90, and the knock-down of HDAC6 by its siRNA induced the acetylation of HSP80 and α-tubulin, indicating that HDAC 6 is also an HSP 90 deacetylase.
Journal ArticleDOI
Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family
TL;DR: The results indicate that HDAC11 is a novel and unique member of the histone deacetylase family and it may have distinct physiological roles from those of the known HDACs.
Journal ArticleDOI
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Wei Qi,Ho Man Chan,Lin Teng,Ling Li,Shannon Chuai,Ruipeng Zhang,Jue Zeng,Min Li,Hong Fan,Ying Lin,Justin Gu,Ophelia Ardayfio,Ji-Hu Zhang,Xiaoxia Yan,Jialuo Fang,Yuan Mi,Man Zhang,Tao Zhou,Grace Feng,Zijun Chen,Guobin Li,Teddy T.C. Yang,Kehao Zhao,Xianghui Liu,Zhengtian Yu,Chris Lu,Peter Atadja,En Li +27 more
TL;DR: A potent and selective small molecule inhibitor, EI1, is developed, which inhibits the enzymatic activity of Ezh2 through direct binding to the enzyme and competing with the methyl group donor S-Adenosyl methionine, providing strong validation of EzH2 as a potential therapeutic target for the treatment of cancer.
Journal ArticleDOI
Epigenetics in cancer: Targeting chromatin modifications
TL;DR: A number of compounds targeting enzymes that regulate histone acetylation, histone methylation, and DNA methylation have been developed as epigenetic therapies, with some demonstrating efficacy in hematological malignancies and solid tumors.